Delcath Systems Inc
NASDAQ:DCTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (5.2), the stock would be worth $16.79 (65% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.2 | $10.18 |
0%
|
| 3-Year Average | 5.2 | $16.79 |
+65%
|
| 5-Year Average | 4.8 | $15.31 |
+50%
|
| Industry Average | 3.1 | $10.01 |
-2%
|
| Country Average | 2.5 | $8.06 |
-21%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Delcath Systems Inc
NASDAQ:DCTH
|
366m USD | 3.2 | 130.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 9 | 56.3 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 3.1 | 25.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 5.4 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 2.1 | 22.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 3.5 | 23.6 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 4.6 | 43.4 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 2.1 | 18.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 27.2 | 41.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 1.7 | 23.8 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 4.9 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Delcath Systems Inc
Glance View
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.
